Health Sciences Welcomes Irma Grossi as Senior Director of Life Sciences and ToxicologyIrma Grossi, formerly of Batelle, has joined RTI's Health Sciences Unit as senior director of life sciences and toxicology.
Dr. Irma M. Grossi is Senior Director of Preclinical Pharmaceutical Sciences at RTI-HS, where she is responsible for managing professional and support staff in the planning and implementation of preclinical development programs for new lead candidates.She develops project plans and budgets and monitors technical and financial performance of LST projects, establishing and monitoring corrective action when required.
Dr. Grossi has 12 years of experience in preclinical drug development toward investigational new drug (IND) application filings with responsibilities in Good Laboratory Practices (GLP) toxicology ranging from appointments as Study Director/Senior Study Director/Team Leader (IRDC/MPI Research and Battelle Memorial Institute), Laboratory Director (Liberty Research), and Program Manager/Toxicology Manager (Battelle Memorial Institute) to establishing and operating a GLP Toxicology Department for an animal health production and supply company (Liberty Research).Her experience includes conducting, supervising, and coordinating of individual acute, repeat dose, subchronic and chronic toxicology studies for the commercial industry and for the National Cancer Institute (NCI).
Dr. Grossi has managed various preclinical toxicology programs and staff who provide drug development support for IND and new drug application (NDA) submissions to the US Food and Drug Administration (FDA), as well as support for the US Environmental Protection Agency (EPA) and European registrations for industrial and government clients.
She has extensive experience with leading multidisciplinary teams in performing various programs for NCI, biotechnologies, and multinational pharmaceutical companies.Dr. Grossi has served as the Principal Investigator (PI) on multiyear contracts for anti-AIDS therapies and antineoplastic drugs for the NCI Toxicology and Pharmacology Branch, the Developmental Therapeutics Program, and the Division of Cancer Treatment and Diagnosis.She was the focal point of all program communications and was responsible for the technical and fiscal components for studies associated with each contract.
Her work in toxicology and pharmacokinetics has appeared in many publications, including numerous peer-reviewed journal articles and abstracts, and she has authored or coauthored eight book chapters.
Email Irma Grossi
Health Economics & Solutions - Pharmacoepidemiology & Outcomes Research - RTI International
Irma "Gina" Grossi, PhD, joined RTI in 2005 as senior director of life sciences and toxicology.Dr. Grossi has extensive experience in drug safety and evaluation, joining RTI after eight years in a variety of high-level research positions at Battelle Memorial Institute.Most recently, she served as manager of commercial toxicology and senior program director for Battelle's multimillion dollar per year toxicology division.Dr. Grossi is well-known in the toxicology field, having authored or coauthored eight book chapters and numerous peer-reviewed journal articles and abstracts.She is a frequent speaker at seminars around the world on topics such as drug development, cancer metastasis, and the effect of virus infection on brain function.Dr. Grossi is a member of the Society of Toxicology, American Association for the Advancement of Science, Women in Cancer Research, and American College of Toxicology.
Parise, R.A., Sparrow, B.R., Merrill, J.W., Grossi, I.M., Covey, J.M., et al. (2004 Oct 15).Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of halofuginone in plasma.Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 810 (1):35-40. Dahl, A.R., Grossi, I.M., Houchens, D.P., Scovell, L.J., Placke, M.E., et al. (2000 Aug).Inhaled isotretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: a pilot study.Clinical Cancer Research, 6 (8):3015-3024. Honn, K.V., Tang, D.G., Grossi, I., Duniec, Z.M., Timar, J., et al. (1994 Jan 15).Tumor cell-derived 12(S)-hydroxyeicosatetraenoic acid induces microvascular endothelial cell retraction.Cancer Research, 54 (2):565-574. Honn, K.V., Tang, D.G., Grossi, I.M., Renaud, C., Duniec, Z.M., et al. (1994 Jan).Enhanced endothelial cell retraction mediated by 12(S)-HETE: a proposed mechanism for the role of platelets in tumor cell metastasis.Experimental Cell Research, 210 (1):1-9. Chen, Y.Q., Gao, X., Timar, J., Tang, D., Grossi, I.M., et al. (1992 Aug 25).Identification of the alpha IIb beta 3 integrin in murine tumor cells.Journal of Biological Chemistry, 267 (24):17314-17320. Honn, K.V., Grossi, I.M., Diglio, C.A., Wojtukiewicz, M., & Taylor, J.D. (1989 Sep).Enhanced tumor cell adhesion to the subendothelial matrix resulting from 12(S)-HETE-induced endothelial cell retraction.Faseb Journal, 3 (11):2285-2293. Grossi, I.M., Fitzgerald, L.A., Umbarger, L.A., Nelson, K.K., Diglio, C.A., et al. (1989 Feb 15).Bidirectional control of membrane expression and/or activation of the tumor cell IRGpIIb/IIIa receptor and tumor cell adhesion by lipoxygenase products of arachidonic acid and linoleic acid.Cancer Research, 49 (4):1029-1037. Grossi, I.M., Hatfield, J.S., Fitzgerald, L.A., Newcombe, M., Taylor, J.D., et al. (1988 May).Role of tumor cell glycoproteins immunologically related to glycoproteins Ib and IIb/IIIa in tumor cell-platelet and tumor cell-matrix interactions.Faseb Journal, 2 (8):2385-2395. Grossi, I.M., Fitzgerald, L.A., Kendall, A., Taylor, J.D., Sloane, B.F., et al. (1987 Dec).
Thank You for Downloading!
1. Download ZoomInfo Grow
2. Run Installation Wizard
3. Check your inbox to Sign in to ZoomInfo Grow